Results 121 to 127 of about 427 (127)

An Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds

Case Medical Research, 2020

semanticscholar   +2 more sources

A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001

Case Medical Research, 2019

semanticscholar   +2 more sources

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris

Case Medical Research, 2019

semanticscholar   +2 more sources

How urgent is the need for new antifungals?

Expert Opinion on Pharmacotherapy, 2021
Introduction: Invasive fungal infection carries a high morbidity, mortality and economic cost. In recent times, a rising incidence of fungal infection and antifungal resistance is occurring which has prompted the development of novel antifungal agents ...
Adam G. Stewart, D. Paterson
semanticscholar   +1 more source

Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix

Pharmacotherapy
Management of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp.
Benjamin A August, P. Kale-Pradhan
semanticscholar   +1 more source

Salvage Therapy for the Treatment of Mucormycosis

Current Treatment Options in Infectious Diseases, 2021
Ashka Patel, J. Bork, D. Riedel
semanticscholar   +1 more source

Drugs in Clinical Development for Fungal Infections

Drugs, 2017
M. González-Lara, J. Sifuentes-Osornio, L. Ostrosky-Zeichner   +2 more
semanticscholar   +1 more source